Clean Science Q1 FY27: HALS scale-up drives record consolidated sales amid supply chain volatility

Clean Science and Technology reported its highest-ever consolidated quarterly sales in Q1 FY27, even as management acknowledged a tough operating backdrop. Geopolitical disruptions affected raw material supply chains, and the non-availability of shipping vessels delayed exports. Despite those constraints, the company delivered sequential improvement and continued to expand the strategic importance of its HALS platform within the portfolio.

On a consolidated basis, sale of products rose to INR 264 crore in Q1 FY27, up 7% quarter-on-quarter and 10% year-on-year. Total consolidated revenue, including other operating income, stood at INR 268 crore. Consolidated EBITDA was INR 96 crore with an EBITDA margin of 36.5%, while profit after tax was INR 73 crore with a PAT margin of 27.8%.

Standalone performance remained resilient. Total revenue was INR 207 crore, up 5% QoQ but down 6% YoY. Standalone EBITDA came in at INR 87 crore, and PAT was INR 73 crore. Management attributed the year-on-year revenue moderation primarily to lower volumes caused by supply-side disruptions, including about two weeks of production impact.

A quarter where performance chemicals took a larger share

The company’s consolidated revenue mix tilted further toward performance chemicals. In Q1 FY27, performance chemicals accounted for 81% of consolidated revenue, up from 74% in Q1 FY26. Pharma and agro intermediates declined to 12% from 16%, while FMCG chemicals declined to 7% from 10%.

Within the performance segment, HALS continued to be the key growth driver. Management stated HALS now accounts for 22% of sales and that the company has materially reduced reliance on the top four legacy products. The share of those products has declined from around 85% in Q4 FY23 to around 60% in Q1 FY27. The company positioned this as an important derisking step, as newer grades and a broader basket begin to contribute.

A notable operational milestone was achieved at the subsidiary level. Clean Fino Chem Ltd. (CFCL), which houses the HALS facility, reached what management called an operationally self-sustaining phase, having fully recovered operating expenses. The company described this as a shift from an investment phase toward a monetization phase.

Financial snapshot: standalone vs consolidated

The difference in margins between standalone and consolidated results continues to reflect the group’s scaling phase at CFCL. Consolidated raw material costs were 39.7% of revenue in Q1 FY27 versus 35.0% in Q1 FY26, indicating input cost pressure. Management linked raw material volatility to the Middle East crisis and crude-related movements, noting that full pass-through is not always possible, particularly where long-term customer contracts are in place.

HALS: improving mix, rising exports, and a new technology partnership

Management provided additional operating detail on HALS during the earnings call. HALS volumes were stated to be in the range of about 1,000 tons in Q1 FY27. The company described an improving product mix, moving toward higher grades. Management indicated that average prices moved from around 440 to around 550, and that the contribution of HALS 770 reduced as higher grades grew. Exports also increased meaningfully. While the first year of HALS sales was entirely domestic, management said the current quarter saw exports contribute nearly 50% of HALS sales.

The quarter also included a strategic collaboration that could expand the HALS addressable market. Clean Science announced a collaboration with a Swiss partner, Geneus Chem. Management described Geneus as a technology partner with patented advanced HALS products, specifically in the NOR HALS category. The company confirmed that tech transfer would occur and that the products would be manufactured at Clean Fino Chem, with co-branding and geography-based marketing to avoid channel conflict.

Importantly, management disclosed several measurable elements of this partnership:

• Production for the Geneus-linked products is expected to start in Q3 FY27.
• The company expects cumulative additional revenue of INR 300 to 350 crore over a 3 to 4-year period from this partnership.
• Management stated there is no transfer fee or royalty, and that capex for this plant is expected to be around INR 25 crore.

Management also suggested that these advanced HALS grades should carry higher margins compared to the existing HALS basket, given their niche applications, including agricultural films used in harsher environments.

Capex, new capacity, and global footprint expansion

Capex continued to be directed toward scaling the subsidiary platform. The investor presentation noted that the company incurred about INR 100 crore of capex during Q1 FY27 toward investment in CFCL. During the concall, management added that total investment in the subsidiary stands at about INR 850 crore and stated that all future new products and new lines would be implemented at CFCL.

The company also outlined a geographic expansion initiative. Clean Science stated it is establishing a wholly owned European subsidiary to expand its global footprint and improve customer proximity. In the concall, management said the subsidiary would be started in mid-September and operational from then, and would cater to Europe demand.

On the manufacturing pipeline, Performance Chemical 2 was highlighted as a key upcoming project. The presentation indicated commercialization by Q3 FY27, but management later guided to a delay due to labor issues. They now expect commercialization around November, followed by a stabilization phase through Q4, with major revenues expected only from Q1 of the next financial year.

Management also provided an update on hydroquinone and catechol, stating that stabilization is largely completed, customer approvals have been received, and the company is ramping up for commercial supplies. They expect a gradual increase in revenue as production scales.

What to track from here

Q1 FY27 reinforced a clear direction for Clean Science: expand the performance chemicals platform, scale HALS into a larger and more diversified profit pool, and build differentiated capability through technology partnerships. The quarter also highlighted ongoing external risks. Shipping availability, supply disruptions, and crude-linked raw material volatility remain variables that can affect volume and margins.

For investors, the next checkpoints will likely be the pace of HALS export ramp-up, the commissioning and stabilization of Performance Chemical 2, and early progress on the Geneus collaboration as production starts in Q3 FY27. The company’s messaging stayed grounded in operating realities, while still providing time-bound updates and quantified revenue potential for key initiatives.